Can AI truly revolutionize molecular biology if it’s built on unreliable data? In this game-changing episode, we speak with Dr. Jonathon O'Brien, founder and CEO of Golgi, about one of the most critical—and often overlooked—issues in biomedical AI: data reliability.With a background in biostatistics, proteomics, and machine learning, Dr. O’Brien shares how Golgi’s AI-powered computational platform is helping pharma and biotech giants like Johnson & Johnson tackle the reproducibility crisis in mass spectrometry-based proteomics. We explore how his patented platform predicts measurement variability using data features most researchers overlook—and how this unlocks faster, cheaper, and more reliable drug discovery.What You’ll Learn:Why AI models in biology often fail due to bad training dataHow Golgi predicts data reliability without replicatesWhy reproducibility and variance prediction are key to high-throughput drug screeningReal-world examples from pharma and stealth biotech clientsThe cultural and technical barriers to trustworthy AI in life sciencesLessons from AlphaFold and Basecamp Research on reliable ML data useBest practices for applying machine learning in molecular biologyHow human expertise is still vital in AI-driven biomedical innovationAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
Reducing Burnout and Boosting Revenue in ASCs
10 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast
Dr. Erich G. Anderer, Chief of the Division of Neurosurgery and Surgical Director of Perioperative Services at NYU Langone Hospital–Brooklyn
09 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast
Dr. Nolan Wessell, Assistant Professor and Well-being Co-Director, Department of Orthopedic Surgery, Division of Spine Surgery, University of Colorado School of Medicine
08 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast
NPR News: 12-08-2025 2AM EST
08 Dec 2025
NPR News Now
NPR News: 12-08-2025 1AM EST
08 Dec 2025
NPR News Now